UNSPSC 51283802: Pristinamycin or pristinamycine

This classification denotes an antibiotic with the molecular formula C34H50N4O9S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9M4FJE48E, chemically known as virginiamycin m1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26r,27s)- but generally known as dalfopristin, which bears US NIH Compound Identifier 6323289. European Medicines Agency schedules Dalfopristin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06892MIG.

The term DALFOPRISTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DALFOPRISTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(C1C2N(CC1)C(=O)C1NC(OC1)CC(=O)CC(O)C=C(C=CCNC(=O)C=CC(C(OC2=O)C(C)C)C)C)CCN(CC)CC.

UNSPSC 51283802 Pristinamycin or pristinamycine is a Commodity code that nominally covers an antibiotic pharmaceutical product, but the recent state and local opportunities tagged under it do not reflect procurement of pristinamycin itself. Instead, the code shows activity for broader pharmaceutical supply and community health product procurement. State and local issuing bodies use this code to solicit antibiotics, naloxone, and drug deactivation systems through competitive bidding and cooperative purchasing vehicles. The mix of issuing bodies includes state health departments and county governments sourcing pharmaceutical supplies and emergency response products to support public health and community safety initiatives.

Geographic activity centers on Florida and Illinois. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for supply of Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, totaling $2,999,999.11 over the contract life with an initial 12-month term and renewal options for years 2 and 3 (IFB process, award date August 28, 2026). Seminole County, Florida issued an IFB in June 2026 for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building, Sanford, with a response deadline of July 26, 2023 (response date appears historically inconsistent with posting date). Both procurements required electronic bid submission and included compliance requirements such as drug-free workplace certification and E-Verify.